Amedisys (AMED) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Piper Jaffray Raises Price Target as Amedisys (AMED) Raises Acquisition Pipeline
November 6, 2015 11:44 AM ESTPiper Jaffray reiterated a Neutral rating on Amedisys (NASDAQ: AMED), and raised the price target to $45.00 (from $42.00), following the company's 3Q report. AMED's acquisition pipeline has increased from 17 potential targets a year ago to over 300. While deal valuations have increased to... More
